Français

abreva is a topical cold sore treatment with docosanol (cream, 10%), a viral blocking agent that modifies the cell membrane and helps block the virus from entering host cells.¹ abreva is indicated for the treatment of acute episodes of recurrent oral-facial herpes simplex labialis. The most frequently reported adverse events were headache (10.4%), application site reaction (2.9%), rash (0.5%), pruritis (0.4%), dry skin (0.4%), and acne (0.3%). The adverse events reported were similar for abreva and placebo.¹
No evidence of contact sensitization or photoallergy was observed in clinical trials.¹
* Pain, burning, itching, tingling.
1. Abreva® (docosanol cream, 10%) Product Monograph. GSK Consumer Healthcare Inc., July 23, 2008.
2. Drugstore Canada & L'actualité pharmaceutique 2010/2011 Survey on OTC Counselling & Recommendations